Opioid induced bowel disease: A twenty-first century physicians' dilemma: Considering pathophysiology and treatment strategies topical collection on neuromuscular disorders of the gastrointestinal tract

Current Gastroenterology Reports

Volumn 15, Issue 7, 2013, Pages

  Sharma, Ankush ^a   Jamal, M Mazen ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer associated constipation; Constipation; Lubiprostone; Methylnaltrexone; Non cancer associated constipation; OBD; OIBD; Opioid induced bowel dysfunction; Opioid induced constipation

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; BENZODIAZEPINE DERIVATIVE; BISACODYL; CELLULOSE; CLONIDINE; DOCUSATE SODIUM; ISPAGULA; LACTULOSE; LAXATIVE; LUBIPROSTONE; MACROGOL; MAGNESIUM CITRATE; MU OPIATE RECEPTOR; NALOXONE; OPIATE; PLACEBO; SENNA EXTRACT; SEROTONIN UPTAKE INHIBITOR; SORBITOL; TRICYCLIC ANTIDEPRESSANT AGENT; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ANALGESIA; ANOREXIA; ARTICLE; BLOATING; CANCER PAIN; CLINICAL TRIAL (TOPIC); CONSTIPATION; DOCTOR PATIENT RELATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; INTESTINE MOTILITY; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NARCOTIC BOWEL SYNDROME; NAUSEA AND VOMITING; NONHUMAN; OPIATE INDUCED INTESTINE DISEASE; PAIN; PATHOPHYSIOLOGY; PHYSICIAN ATTITUDE; POSTOPERATIVE PAIN; QUALITY OF LIFE; RECEPTOR UPREGULATION; SIDE EFFECT; STOMACH EMPTYING; TREATMENT OUTCOME; CHEMICALLY INDUCED; INTESTINAL DISEASES;

ANALGESICS, OPIOID; CONSTIPATION; HUMANS; INTESTINAL DISEASES; LAXATIVES; NARCOTIC ANTAGONISTS;

EID: 84891455252     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-013-0334-4     Document Type: Article

References (31)

1. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290:2443-54. (Pubitemid 37430544)
2. Quigley C. The role of opioids in cancer pain. BMJ. 2005;331:825-9. (Pubitemid 41442365)
3. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106:835-42.
4. Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage. 2002;24:71-90.
5. Watkins, K. Utlization of Methylnaltrexone for Opioid Induced Constipation in an Oncology Hospital. P&T January 2011; Vol 36 No 1
6. Kalso E, Edwards JE, Moore A, et al. Opioids in chronic non cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372-80. (Pubitemid 39550738)
7. Klepstad P et al. Effects on cancer patients' health related quality of life after the start of morphine therapy. J Pain Symptom Manage. 2000;20:19-26. (Pubitemid 30628578)
8. Moss J. Development of peripheral opioid antagonists: new insight into opioid effects. Mayo Clin Proc. 2008;83(10):1116-30.
9. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649-71. (Pubitemid 36408072)
10. Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs. 2007;16:181-94. (Pubitemid 46206632)
11. Rang HP, Dale MM, Ritter JM. Analgesic drugs. Pharmacology. 1999;13:579-603.
12. Gutstein HB, Akil H. In: Hardman JG, Limbird LE, Gilman AG, editors. Goddman & Gilman's The pharmacologic basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 569-619.
13. McMillan S. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control. 2004;11(3).
14. De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996;69:103-15. (Pubitemid 26111425)
15. •• Bell TJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survery(PROBE 1). Pain Med. 2009;10(1):35-42. This study showed that OBD occurs frequently, despite the use of laxatives, in individuals taking daily oral opioids for chronic pain. These gastrointestinal symptoms add to the burden already experienced by chronic pain patients, negatively impacting quality of life and, in some cases, affecting opioid treatment itself.
16. Panchal SJ et al. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61(7):1181-7. (Pubitemid 46934629)
17. Yuan CS, Foss JF, O'conner, et al. Gut motility and transit changes in patients receiving long term methadone maintenance. J Clin Pharmacol. 1998;38(10):931-5. (Pubitemid 28482119)
18. •• Grunkemeier DMS, Cassara JE, Dalton CB. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol. 2007;5:1126-39. This study explained in detailed the phenomenon of NBS and that an effective physician patient relationship and a graded withdrawal program reduced withdrawal effects. (Pubitemid 47488969)
19. Rogers M, Cerda JJ. Editorial: the narcotic bowel syndrome. J Clin Gastroenterol. 1989;11:132-5.
20. McMillan SC, Tittle M, Hagan S, et al. Management of pain and pain-related symptoms in hospitalized veterans with cancer. Cancer Nurs. 2000;23:327-36.
21. •• Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332-43. This study proved subcutaneous methylnaltrexone was efficacious in rapidly inducing laxation and was generally well tolerated in patients with advanced illness and OIC. (Pubitemid 351749157)
22. Yuan CS et al. Handbook of opioid bowel dysfunction. New York: Haworth Medical Press: Haworth Reference Press, 2005. http://pain-topics.com/education- CME-locator/indexbkrv.php#opioidbowel. Access checked 02/2013
23. Culpepper-Morgan JA et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther. 1992;52(1):90-5.
24. Cheskin LJ, Chami TN, et al. Assessment of nalmefene glucoronide as a selective gut opioid antagonist. Drug Alcohol Depend. 1995;39(2):151-4.
25. Goodheart CR, Leavitt SB, et al. Managing Opioid-Induced Consipation in Ambulatory-Care Patients. Pain Treatment Topics August 2006: 1-8
26. Tack J. Current and future therapies for chronic constipation. Best Pract Res Clin Gastroenterol. 2011;25:151-8.
27. Crownover B, Zimmerman E. Methylnaltrexone for opioid induced constipation. Am Fam Physician. 2010;82(6):678-81.
28. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting mu opioid receptor antagonist for the treatment of opioid induced bowel dysfunction - a 21 day treatment-randomized clinical trial. J Pain. 2005;6:184-92. (Pubitemid 40365022)
29. Jamal et al. Oral Lubiprostone for Opioid-Induced Constipation in Non-Cancer Pain. New England Journal of Medicine 2013
30. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A Supp):11S-8S. (Pubitemid 34072942)
31. Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer. 1998;6:356-64. (Pubitemid 28337126)